Bristol Myers Squibb led a $237 million Series E in Pathos AI, lifting the startup’s valuation to about $3 billion as it scales an AI-driven drug development engine. The company says its platform, Foundry, deploys thousands of specialized AI agents to synthesize clinical, genomic, and specimen data to decide next steps across active oncology programs. The capital is earmarked to scale Foundry and push multiple assets toward milestone-driven registrational planning, including JSKN-016 and programs spanning prostate cancer, multiple myeloma, MET-altered NSCLC, and TROP2/HER3-expressing tumors. The round reflects ongoing big-deal interest in agentic AI systems that can operationalize decision-making within drug development pipelines rather than only supporting research discovery.